### ü§ñ Oncology Research - VERITAC-2 Trial Results

This article summarizes the primary results of the VERITAC-2 clinical trial, comparing vepdegestrant to fulvestrant in ER+/HER2‚Äì metastatic breast cancer patients post-CDK4/6i.  The focus is on progression-free survival (PFS) and objective response rate (ORR).

Key Points:

‚Ä¢ Significant PFS improvement observed in ESR1-mut+ patients with vepdegestrant.


‚Ä¢  No statistically significant difference in PFS observed in the ITT population.


‚Ä¢ Higher ORR observed in ESR1-mut+ patients treated with vepdegestrant.



üîó Resources:

‚Ä¢ [Larvol](https://x.com/Larvol) - Oncology expert


‚Ä¢ [SuyogCancer](https://x.com/SuyogCancer) - Oncology researcher


![Image](https://pbs.twimg.com/media/GsRvVa5WAAAZWCp?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/GsRvXkLX0AAANK_?format=jpg&name=360x360)
![Image](https://pbs.twimg.com/media/GsRvXkKX0AAkuzb?format=jpg&name=360x360)


---

### ü§ñ Oncology Research - DESTINY-Gastric04 Trial Results

This article presents a summary of the DESTINY-Gastric04 trial comparing T-DXd to ramucirumab+paclitaxel in patients with HER2+ gastroesophageal junction or gastric adenocarcinoma. Key findings regarding overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) are highlighted.

Key Points:

‚Ä¢ T-DXd demonstrated a statistically significant improvement in overall survival.


‚Ä¢  A modest improvement in progression-free survival was observed with T-DXd.


‚Ä¢  Higher objective response rate was seen in the T-DXd arm.



üîó Resources:

‚Ä¢ [Larvol](https://x.com/Larvol) - Oncology expert


‚Ä¢ [SuyogCancer](https://x.com/SuyogCancer) - Oncology researcher


![Image](https://pbs.twimg.com/media/GsRwfreX0AACkX2?format=jpg&name=360x360)
![Image](https://pbs.twimg.com/media/GsRwgaTWMAAYeNg?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/GsRwhFNXYAAy-40?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/GsRwh2NXgAAq_EK?format=jpg&name=small)


---

### ü§ñ Oncology Research - INAVO120 Trial Results

This article summarizes the results of the INAVO120 trial, evaluating a triplet combination therapy (inavolisib + palbociclib + fulvestrant) in patients with PIK3CA-mutant, HR+/HER2‚Äì advanced breast cancer. The key findings focus on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).

Key Points:

‚Ä¢ Statistically significant improvement in overall survival observed with the triplet regimen.


‚Ä¢  Marked improvement in progression-free survival seen with the triplet therapy.


‚Ä¢  Substantially higher objective response rate achieved with the triplet regimen.



üîó Resources:

‚Ä¢ [Larvol](https://x.com/Larvol) - Oncology expert


‚Ä¢ [SuyogCancer](https://x.com/SuyogCancer) - Oncology researcher


![Image](https://pbs.twimg.com/media/GsRyzBLWYAA7k3_?format=jpg&name=360x360)
![Image](https://pbs.twimg.com/media/GsRy0HzW0AAifUO?format=jpg&name=360x360)
![Image](https://pbs.twimg.com/media/GsRy0m8WAAA7J6s?format=jpg&name=360x360)
![Image](https://pbs.twimg.com/media/GsRy1DYXkAAIf43?format=jpg&name=360x360)


---

### ü§ñ AI in Oncology - Massive Bio at ASCO 2025

This article briefly describes Massive Bio's presence and activities at the ASCO 2025 conference, focusing on their contributions to oncology through AI-powered solutions.

Key Points:

‚Ä¢  Advancement of oncology through AI-powered clinical trial matching.


‚Ä¢  Contribution to oncology through real-world data solutions.


‚Ä¢  Focus on collaborative intelligence in oncology research.



üîó Resources:

‚Ä¢ [MassiveBio](https://x.com/MassiveBio) - AI solutions for oncology


‚Ä¢ [ASCO](https://x.com/ASCO) - American Society of Clinical Oncology


![Image](https://pbs.twimg.com/media/GsMyC5BWkAA62fN?format=jpg&name=small)


---

### üöÄ Medical Technology - Butterfly iQ Ultrasound Discount

This article announces a limited-time discount on Butterfly iQ3 and iQ+ ultrasound devices for students and residents.

Key Points:

‚Ä¢ Discounted pricing for Butterfly iQ3 and iQ+.


‚Ä¢ Limited-time offer for students and residents.



üîó Resources:

‚Ä¢ [Butterfly Network](https://bit.ly/3Sx6MOo) -  Ultrasound device


![Image](https://pbs.twimg.com/ext_tw_video_thumb/1928436285053538304/pu/img/9JQ3uW10HrnY6nGC.jpg)


---

### ü§ñ AI in Global Health - Qure.ai at WHA78

This article summarizes Qure.ai's participation in a panel discussion at the 78th World Health Assembly (WHA78) on leveraging AI to improve efficiency and impact in global health.

Key Points:

‚Ä¢  Focus on maximizing the impact of investments in health systems.


‚Ä¢  Panel discussion on using AI to achieve "more with less" in global health.


‚Ä¢  Collaboration between Ministries of Health, global funders, NGOs, and the private sector.



üîó Resources:

‚Ä¢ [Qure.ai](https://x.com/qure_ai) - AI solutions for healthcare


![Image](https://pbs.twimg.com/amplify_video_thumb/1928075728945594368/img/Pw2g5UPBcZie2w5X.jpg)


---

### ü§ñ AI in Healthcare - Rad AI at RSNA

This article highlights the impact of AI in healthcare as perceived by Rad AI's Lead Product Manager, Chris Walker, following his experience at RSNA.

Key Points:

‚Ä¢ AI's impact in healthcare is no longer theoretical but is happening at scale.



üîó Resources:

‚Ä¢ [Rad AI](https://x.com/radai) - AI solutions for radiology



![Image](https://pbs.twimg.com/ext_tw_video_thumb/1928074086342615040/pu/img/Bw_vGvIgnJAYsu4y.jpg)


---

### ü§ñ AI in Mental Healthcare - Spectruth DAO x AxonDAO

This article announces a collaboration between Spectruth DAO and AxonDAO to provide real-time AI support for mental healthcare, focusing on PTSD.

Key Points:

‚Ä¢  Commitment to bringing precision mental health care to everyone.


‚Ä¢  Focus on those most at risk for PTSD.


‚Ä¢  Collaboration between Spectruth DAO and AxonDAO.



üîó Resources:

‚Ä¢ [Spectruth AI](https://x.com/SpectruthAI) - AI for mental health


‚Ä¢ [AxonDAO](https://x.com/AxonDAO) -  Decentralized autonomous organization focused on mental health


---

### ü§ñ Oncology Research - HER2DX Prognostic Value in Early Breast Cancer

This article discusses a study presented at ASCO 2025 on the prognostic value of HER2DX in older patients with HER2-positive early breast cancer.

Key Points:

‚Ä¢  Study on HER2DX prognostic value in older patients with HER2-positive early breast cancer.


‚Ä¢  Data from the RESPECT phase III trial.


‚Ä¢  Collaboration with Prof. Aleix Prat and REVEAL GENOMICS.



üîó Resources:

‚Ä¢ [Larvol](https://x.com/Larvol) - Oncology expert


‚Ä¢ [Kazuki Nozawa](https://x.com/kazuki_nozawa) - Researcher


‚Ä¢ [Reveal Genomics](https://reveal-genomics.com/press-releases/asco-2025-reveal-genomics-unveils-new-her2dx-data-from-800-patients‚Ä¶) - Genomics research


![Image](https://pbs.twimg.com/media/GsEQQq2aYAATgqe?format=jpg&name=medium)


---

### ü§ñ AI in Lung Cancer Care - Qure.ai in Goa, India

This article describes Goa, India's implementation of AI-powered lung cancer screening at a statewide scale.

Key Points:

‚Ä¢  Goa is the first state in India to deploy AI-powered lung cancer screening statewide.


‚Ä¢  Use of AI in pioneering lung cancer care.



üîó Resources:

‚Ä¢ [Qure.ai](https://x.com/qure_ai) - AI solutions for healthcare


‚Ä¢ [Visrane](https://x.com/visrane) -  Healthcare technology company


![Image](https://pbs.twimg.com/media/GsCX7sVbAAEQhTB?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/GsCX7r1W8AAJgFI?format=jpg&name=small)


---

### ‚≠êÔ∏è Support

If you liked reading this report, please star ‚≠êÔ∏è this repository and follow me on [Github](https://github.com/Drix10), [ùïè (previously known as Twitter)](https://x.com/DRIX_10_) to help others discover these resources and regular updates.

---